Advertisement


Lynda Chin, MD, on the Landscape and Future of Digital Medicine

SITC 2021

Advertisement

Lynda Chin, MD, of the University of Texas, Austin Dell Medical School and Apricity Health, discusses precision medicine, barriers to its progress, and the challenges that must be met to facilitate better outcomes for patients. Building evidence and trust is key, Dr. Chin explains, as is developing an infrastructure that allows more clinicians to take part in the process.



Related Videos

Immunotherapy

Patrick Hwu, MD, and Mary Dean, JD, CAE, on What’s Ahead for Cancer Immunology and SITC

Patrick Hwu, MD, of Moffitt Cancer Center and President of the Society for Immunotherapy of Cancer (SITC), and Mary Dean, JD, CAE, SITC Executive Director, discuss the organization’s mission, strides made in cancer immunology, meeting the challenge of immunoresistance, and the new SITC app for clinical practice guidelines. This app places a useful tool in the hands of health-care providers, one that can be continually updated as the science evolves.

Lung Cancer
Immunotherapy

Stephanie T. Schmidt, PhD, on NSCLC: The Immunomodulatory Impact of Neoadjuvant Chemotherapy and Immune-Based Treatments

Stephanie T. Schmidt, PhD, of The University of Texas MD Anderson Cancer Center, discusses the first integrated examination of the immunomodulatory effects of neoadjuvant chemotherapy, nivolumab, and nivolumab plus chemotherapy in resected non–small cell lung cancer (Abstract 962).

Solid Tumors
Immunotherapy

Kim A. Reiss, MD, on HER2-Overexpressing Solid Tumors: First-in-Human Study of Anti-HER2 CAR Macrophages

Kim A. Reiss, MD, of the University of Pennsylvania, discusses results of a phase I trial of a CAR-M engineered macrophage cancer therapy, known as CT-0508, for patients with solid tumors that overexpress HER2. CAR-M, designed to exploit the natural role of macrophages to initiate an antitumor response, is currently under study at multiple clinical sites (Abstract 951).

Immunotherapy

Yevgeniy R. Semenov, MD, on Cutaneous Immune-Related Adverse Events and Response to Immune Checkpoint Inhibitors

Yevgeniy R. Semenov, MD, of Massachusetts General Hospital and Harvard Medical School, discusses new findings suggesting cutaneous adverse events such as vitiligo, lichenoid dermatitis, and psoriasis—which often occur in patients with cancer who receive immune checkpoint inhibitors—may be strongly associated with response to therapy and a 22% reduction in mortality (Abstract 814).

 

Skin Cancer
Immunotherapy

John M. Kirkwood, MD, on Melanoma: Early Study Results on Vidutolimod and Pembrolizumab

John M. Kirkwood, MD, of the University of Pittsburgh Medical Center, discusses phase Ib findings on the combination of vidutolimod plus pembrolizumab, as well as vidutolimod monotherapy, both of which showed clinical activity in patients with PD-1 blockade–refractory melanoma. The duration of response with the combination therapy was substantially longer. Phase II studies are ongoing (Abstract 950).

Advertisement

Advertisement



Advertisement